Innovative Financings: Venture Debt for Biotech Companies
30 September 2007Going Public, "Biotechnologie 2007"
More and more biotech companies are looking into new sources of funding in addition to classic financing models of venture capital and partnerships. Some of these alternative financing instruments are very common in leading biotech markets like the USA, but have not yet been widely used in Europe, especially in Germany. This includes venture debt financing. This financing model has lately been increasingly offered in Germany by financial services providers specialized in the life sciences industry, e.g. Silicon Valley Bank or GE Healthcare Financial Services. The article discusses how venture debt works, which biotech companies could benefit from this financing model, advantages of venture debt and what to keep in mind when considering venture debt financing.